# Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

> **NCT01388920** · PHASE2 · TERMINATED · sponsor: **Theratechnologies** · enrollment: 3 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Tesamorelin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01388920
- **Lead sponsor:** Theratechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated based on a non-safety related corporate decision.
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388920, "Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01388920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*